Browse BTG2

Summary
SymbolBTG2
NameBTG family, member 2
Aliases TIS21; MGC126063; MGC126064; B-cell translocation gene 2; pheochromacytoma cell-3; NGF-inducible anti-prolif ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF07742 BTG family
Function

Anti-proliferative protein; the function is mediated by association with deadenylase subunits of the CCR4-NOT complex. Activates mRNA deadenylation in a CNOT6 and CNOT7-dependent manner. In vitro can inhibit deadenylase activity of CNOT7 and CNOT8. Involved in cell cycle regulation. Could be involved in the growth arrest and differentiation of the neuronal precursors (By similarity). Modulates transcription regulation mediated by ESR1. Involved in mitochondrial depolarization and neurite outgrowth.

> Gene Ontology
 
Biological Process GO:0000075 cell cycle checkpoint
GO:0000077 DNA damage checkpoint
GO:0000082 G1/S transition of mitotic cell cycle
GO:0000288 nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay
GO:0000289 nuclear-transcribed mRNA poly(A) tail shortening
GO:0000956 nuclear-transcribed mRNA catabolic process
GO:0003002 regionalization
GO:0006401 RNA catabolic process
GO:0006402 mRNA catabolic process
GO:0006417 regulation of translation
GO:0006479 protein methylation
GO:0006977 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest
GO:0007050 cell cycle arrest
GO:0007093 mitotic cell cycle checkpoint
GO:0007346 regulation of mitotic cell cycle
GO:0007389 pattern specification process
GO:0007517 muscle organ development
GO:0007519 skeletal muscle tissue development
GO:0007611 learning or memory
GO:0007612 learning
GO:0008213 protein alkylation
GO:0008306 associative learning
GO:0009612 response to mechanical stimulus
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0009952 anterior/posterior pattern specification
GO:0010608 posttranscriptional regulation of gene expression
GO:0010948 negative regulation of cell cycle process
GO:0014706 striated muscle tissue development
GO:0017148 negative regulation of translation
GO:0019439 aromatic compound catabolic process
GO:0021537 telencephalon development
GO:0021542 dentate gyrus development
GO:0021543 pallium development
GO:0021761 limbic system development
GO:0021766 hippocampus development
GO:0021953 central nervous system neuron differentiation
GO:0021954 central nervous system neuron development
GO:0030330 DNA damage response, signal transduction by p53 class mediator
GO:0030900 forebrain development
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0031570 DNA integrity checkpoint
GO:0031571 mitotic G1 DNA damage checkpoint
GO:0032259 methylation
GO:0034248 regulation of cellular amide metabolic process
GO:0034249 negative regulation of cellular amide metabolic process
GO:0034655 nucleobase-containing compound catabolic process
GO:0035914 skeletal muscle cell differentiation
GO:0042770 signal transduction in response to DNA damage
GO:0043414 macromolecule methylation
GO:0043434 response to peptide hormone
GO:0043523 regulation of neuron apoptotic process
GO:0043524 negative regulation of neuron apoptotic process
GO:0044270 cellular nitrogen compound catabolic process
GO:0044708 single-organism behavior
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044773 mitotic DNA damage checkpoint
GO:0044774 mitotic DNA integrity checkpoint
GO:0044783 G1 DNA damage checkpoint
GO:0044819 mitotic G1/S transition checkpoint
GO:0044843 cell cycle G1/S phase transition
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0045930 negative regulation of mitotic cell cycle
GO:0046700 heterocycle catabolic process
GO:0050890 cognition
GO:0051402 neuron apoptotic process
GO:0051602 response to electrical stimulus
GO:0060211 regulation of nuclear-transcribed mRNA poly(A) tail shortening
GO:0060213 positive regulation of nuclear-transcribed mRNA poly(A) tail shortening
GO:0060537 muscle tissue development
GO:0060538 skeletal muscle organ development
GO:0061013 regulation of mRNA catabolic process
GO:0061014 positive regulation of mRNA catabolic process
GO:0061351 neural precursor cell proliferation
GO:0070997 neuron death
GO:0071156 regulation of cell cycle arrest
GO:0071158 positive regulation of cell cycle arrest
GO:0072331 signal transduction by p53 class mediator
GO:0072395 signal transduction involved in cell cycle checkpoint
GO:0072401 signal transduction involved in DNA integrity checkpoint
GO:0072413 signal transduction involved in mitotic cell cycle checkpoint
GO:0072422 signal transduction involved in DNA damage checkpoint
GO:0072431 signal transduction involved in mitotic G1 DNA damage checkpoint
GO:0090068 positive regulation of cell cycle process
GO:1900151 regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay
GO:1900153 positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay
GO:1901214 regulation of neuron death
GO:1901215 negative regulation of neuron death
GO:1901361 organic cyclic compound catabolic process
GO:1901652 response to peptide
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1902400 intracellular signal transduction involved in G1 DNA damage checkpoint
GO:1902402 signal transduction involved in mitotic DNA damage checkpoint
GO:1902403 signal transduction involved in mitotic DNA integrity checkpoint
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902807 negative regulation of cell cycle G1/S phase transition
GO:1903311 regulation of mRNA metabolic process
GO:1903313 positive regulation of mRNA metabolic process
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000134 negative regulation of G1/S transition of mitotic cell cycle
GO:2000177 regulation of neural precursor cell proliferation
GO:2000178 negative regulation of neural precursor cell proliferation
Molecular Function GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001078 transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa03018 RNA degradation
Reactome R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes
R-HSA-6804115: TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolBTG2
NameBTG family, member 2
Aliases TIS21; MGC126063; MGC126064; B-cell translocation gene 2; pheochromacytoma cell-3; NGF-inducible anti-prolif ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BTG2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolBTG2
NameBTG family, member 2
Aliases TIS21; MGC126063; MGC126064; B-cell translocation gene 2; pheochromacytoma cell-3; NGF-inducible anti-prolif ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BTG2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 2 Resistant to T-cell proliferation
Summary
SymbolBTG2
NameBTG family, member 2
Aliases TIS21; MGC126063; MGC126064; B-cell translocation gene 2; pheochromacytoma cell-3; NGF-inducible anti-prolif ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BTG2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0130.975
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3020.883
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.240.871
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3980.567
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6920.777
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0230.994
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.340.416
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6810.672
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0240.989
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.850.631
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1120.671
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3350.0318
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of BTG2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolBTG2
NameBTG family, member 2
Aliases TIS21; MGC126063; MGC126064; B-cell translocation gene 2; pheochromacytoma cell-3; NGF-inducible anti-prolif ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BTG2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBTG2
NameBTG family, member 2
Aliases TIS21; MGC126063; MGC126064; B-cell translocation gene 2; pheochromacytoma cell-3; NGF-inducible anti-prolif ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BTG2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BTG2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBTG2
NameBTG family, member 2
Aliases TIS21; MGC126063; MGC126064; B-cell translocation gene 2; pheochromacytoma cell-3; NGF-inducible anti-prolif ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BTG2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBTG2
NameBTG family, member 2
Aliases TIS21; MGC126063; MGC126064; B-cell translocation gene 2; pheochromacytoma cell-3; NGF-inducible anti-prolif ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BTG2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBTG2
NameBTG family, member 2
Aliases TIS21; MGC126063; MGC126064; B-cell translocation gene 2; pheochromacytoma cell-3; NGF-inducible anti-prolif ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BTG2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBTG2
NameBTG family, member 2
Aliases TIS21; MGC126063; MGC126064; B-cell translocation gene 2; pheochromacytoma cell-3; NGF-inducible anti-prolif ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BTG2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.